Get the Stockscreener App
70.51
0.50%
0.35
Pre-market:
70.55
0.04
+0.06%
Centene Corp stock is traded at $70.51, with a volume of 4.69M.
It is up +0.50% in the last 24 hours and up +6.82% over the past month.
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
See More
Previous Close:
$70.16
Open:
$70.41
24h Volume:
4.69M
Relative Volume:
1.11
Market Cap:
$34.83B
Revenue:
$198.10B
Net Income/Loss:
$-6.45B
P/E Ratio:
-5.3643
EPS:
-13.1443
Net Cash Flow:
$7.11B
1W Performance:
+7.88%
1M Performance:
+6.82%
6M Performance:
+80.79%
1Y Performance:
+97.84%
1-Day Range:
$0.00
$0.00
1-Week Range:
$65.08
$71.01
52-Week Range:
$31.63
$71.01
Centene Corp Stock (CNC) Company Profile
Name
Centene Corp
Sector
Industry
Phone
(314) 725-4477
Address
7700 FORSYTH BLVD., ST LOUIS
Compare CNC vs UNH, CVS, ELV, CI, HUM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNC
Centene Corp
|
70.51 | 34.83B | 198.10B | -6.45B | 7.11B | -13.14 |
UNH
Unitedhealth Group Inc
|
406.67 | 365.02B | 450.13B | 14.91B | 23.62B | 15.55 |
CVS
Cvs Health Corp
|
92.58 | 118.41B | 407.94B | 2.90B | 7.39B | 2.2771 |
ELV
Elevance Health Inc
|
428.43 | 92.91B | 201.11B | 4.95B | 6.29B | 22.50 |
CI
Cigna Group
|
298.81 | 78.96B | 278.13B | 6.74B | 7.66B | 23.60 |
HUM
Humana Inc
|
432.20 | 51.90B | 137.20B | 1.15B | 1.27B | 9.3439 |
Centene Corp Stock (CNC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-26 | Upgrade | Argus | Hold → Buy |
| Jun-23-26 | Initiated | RBC Capital Mkts | Sector Perform |
| May-20-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-29-26 | Upgrade | BofA Securities | Underperform → Buy |
| Apr-29-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-05-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-14-25 | Initiated | Goldman | Sell |
| Jul-28-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-23-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | TD Cowen | Buy → Hold |
| Jul-16-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-10-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-02-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-02-25 | Downgrade | UBS | Buy → Neutral |
| Jun-09-25 | Resumed | Morgan Stanley | Overweight |
| Jun-02-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-08-25 | Upgrade | Jefferies | Underperform → Hold |
| Feb-06-25 | Downgrade | Argus | Buy → Hold |
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Dec-13-24 | Upgrade | UBS | Neutral → Buy |
| Dec-10-24 | Downgrade | Jefferies | Hold → Underperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| May-30-24 | Initiated | Robert W. Baird | Neutral |
| Mar-21-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-06-24 | Initiated | Barclays | Overweight |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-05-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-12-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-20-23 | Initiated | UBS | Neutral |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-08-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-23-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-22 | Initiated | Argus | Buy |
| Aug-26-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-28-22 | Resumed | Barclays | Overweight |
| Jul-14-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-21-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jun-17-22 | Initiated | Loop Capital | Buy |
| May-27-22 | Resumed | Bernstein | Outperform |
| May-26-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-07-22 | Resumed | Barclays | Overweight |
| Jan-06-22 | Resumed | JP Morgan | Overweight |
| Dec-14-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-13-21 | Reiterated | BofA Securities | Buy |
| Dec-13-21 | Reiterated | Credit Suisse | Neutral |
| Dec-13-21 | Reiterated | Mizuho | Neutral |
| Dec-13-21 | Reiterated | Oppenheimer | Outperform |
| Dec-13-21 | Reiterated | Stephens | Overweight |
| Dec-13-21 | Reiterated | Truist | Buy |
| Dec-13-21 | Reiterated | Wells Fargo | Overweight |
| Dec-13-21 | Reiterated | Wolfe Research | Outperform |
| Nov-01-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-21 | Initiated | Cowen | Outperform |
| Jul-09-21 | Initiated | Seaport Global Securities | Buy |
| May-19-21 | Initiated | Wells Fargo | Overweight |
| May-11-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-10-21 | Initiated | Mizuho | Neutral |
| Jan-21-21 | Resumed | Goldman | Neutral |
| Jan-15-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-22-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-01-20 | Initiated | SVB Leerink | Outperform |
| Feb-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-03-20 | Resumed | Evercore ISI | Outperform |
| Jan-28-20 | Reiterated | Bernstein | Outperform |
| Jan-06-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Buy |
| May-10-19 | Upgrade | Citigroup | Neutral → Buy |
| Jan-14-19 | Initiated | Stephens | Overweight |
| Oct-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jul-18-18 | Resumed | Citigroup | Neutral |
| Dec-18-17 | Reiterated | Jefferies | Buy |
| Sep-13-17 | Reiterated | Leerink Partners | Mkt Perform |
| Jun-07-17 | Initiated | Morgan Stanley | Overweight |
| May-22-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-05-17 | Initiated | Deutsche Bank | Buy |
| Mar-23-17 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-17 | Reiterated | Barclays | Overweight |
| Feb-07-17 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-04-17 | Initiated | Piper Jaffray | Overweight |
View All
Centene Corp Stock (CNC) Latest News
Can UNH's Focus on Special Needs Plans Strengthen Medicare Growth? - Zacks Investment Research
Centene's Gold Card Push Could Ease CostsBut Will Savings Follow? - Zacks Investment Research
Centene vs. Molina: Which Managed Care Stock Has More Upside? - Zacks Investment Research
How Evidence Can Guide Prevention Investments - Centene Corporation
Centene vs. Molina: Which Managed Care Stock Has More Upside? - Yahoo Finance
Centene vs. Molina: Which Managed Care Stock Has More Upside? - Zacks Investment Research
Form 4 Centene Corp For: 11 October By Investing.com - Investing.com India
Centene Q3 2026 Preview: The Quarter Is Easy, The 2027 Bridge Is Not (NYSE:CNC) - Seeking Alpha
Centene Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Humana rebounds, Aetna slips: Winners and losers in the 2027 MA star ratings - Fierce Healthcare
Cantor Fitzgerald reiterates Centene stock Overweight rating at $75 - Investing.com
ACA plan provider takes the top spot on the managed care list - The Business Journals
Can Oscar Health Turn ACA Marketplace Growth Into Lasting Profits? - Zacks Investment Research
Centene Corp To Redeem $568.66 Mln Of 4.25% Notes Due 2027 On Oct 23, 2026 - TradingView
NH Healthy Families Earns a 4.0 out of 5-Star NCQA Medicaid Health Plan Rating - Centene Corporation
Centene to redeem $568.7M of 4.25% notes due 2027 on Oct. 23 - TradingView
Earnings Preview: What to Expect From Centene's Report - Barchart.com
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy? - Zacks Investment Research
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy? - Zacks Investment Research
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy? - Yahoo Finance
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy? - TradingView
Centene to Offer Expanded Health Access to Eligible Ambetter Members - www.marketscreener.com
Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri - PR Newswire
Centene Narrows Medicare Advantage Footprint as Costs Remain Elevated - Zacks Investment Research
Centene Narrows Medicare Advantage Footprint as Costs Remain Elevated - Yahoo Finance
Buy 5 Growth Stocks to Boost Your Portfolio in Q4 After a Mixed Q3 - Zacks Investment Research
Centene Corp (XBUL:QEN) Stock Price, Trades & News - GuruFocus
Oscar Health Trading at a Premium: Why Should You Still Buy It? - Zacks Investment Research
Centene Corp. stock gains 1.11 percent ahead of Q3 results - AD HOC NEWS
Centene reaffirms 2026 earnings guidance: Centene stock gains 1.68 percent - AD HOC NEWS
Are Investors Undervaluing Centene (CNC) Right Now? - Zacks Investment Research
Are Investors Undervaluing Centene (CNC) Right Now? - Yahoo Finance UK
Are Investors Undervaluing Centene (CNC) Right Now? - Yahoo Finance
Centene Corp (CNC) Stock Up 3.3% and Still Undervalued -- GF Sco - GuruFocus
Centene Corp. stock outperforms competitors on strong trading day - MarketWatch
Centene Corp. stock outperforms competitors on strong trading day - MarketWatch
Centene stock after-hours at EUR 55.62: plus 2.53 percent - AD HOC NEWS
Centene Corporation (CNC) - Yahoo! Finance Canada
Vance's fraud crackdown may raise costs for US health insurers, enrollees - marketscreener.com
Centene Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Centene Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Centene (CNC): Pricing Actions and Profit Stabilization Drive Earnings Recovery - Yahoo Finance
Centene Corporation (CNC) Jumped on Beat-and-Raise Earnings Quarter - Yahoo Finance
Cantor Fitzgerald reiterates Centene stock rating on margin recovery - Investing.com
Best Growth Stocks to Buy for October 1st - Zacks Investment Research
Zacks.com featured highlights include Banco Macro, Centene, Enersys, Gibraltar Industries and Kennametal - Zacks Investment Research
Zacks.com featured highlights include Banco Macro, Centene, Enersys, Gibraltar Industries and Kennametal - Yahoo Finance
A 583-share award at $0 goes to Centene (CNC) director Theodore R. Samuels II. - Stock Titan
After a 603-share grant, Centene (CNC) director Kenneth Tanji holds 13,093 shares. - Stock Titan
A director received 864 shares at Centene (CNC) on September 30, 2026. - Stock Titan
Centene Corp Stock (CNC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Centene Corp Stock (CNC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KOSTER CHRISTOPHER | Officer |
Aug 26 '26 |
Proposed Sale |
66.90 |
56,500 |
3,779,852 |
0 |
| Burdick Kenneth A | Former Director |
Aug 26 '26 |
Proposed Sale |
65.00 |
43,600 |
2,834,000 |
0 |
| KOSTER CHRISTOPHER | Secretary & General Counsel |
Aug 18 '26 |
Sale |
65.36 |
47,603 |
3,111,332 |
305,354 |
| KOSTER CHRISTOPHER | Officer |
Aug 18 '26 |
Proposed Sale |
65.36 |
47,603 |
3,111,262 |
0 |
| Burdick Kenneth A | Former Director |
Aug 05 '26 |
Proposed Sale |
68.15 |
100,000 |
6,815,182 |
0 |
| Burdick Kenneth A | Director |
Jun 10 '26 |
Proposed Sale |
64.55 |
80,000 |
5,164,227 |
0 |
| Burdick Kenneth A | Director |
Jun 10 '26 |
Sale |
64.55 |
80,000 |
5,164,000 |
197,086 |
| Burdick Kenneth A | Director |
Dec 04 '25 |
Sale |
39.00 |
32,796 |
1,279,044 |
272,365 |
| Burdick Kenneth A | Director |
Dec 04 '25 |
Proposed Sale |
39.00 |
32,796 |
1,279,044 |
0 |
| Burdick Kenneth A | Director |
Dec 03 '25 |
Sale |
39.04 |
33,211 |
1,296,557 |
305,161 |
1.12%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):